FIRST EXPERIENCE WITH A NEW MINIATURIZED PUMP-DRIVEN VENOVOENOUS EXTRACORPOREAL CO2 REMOVAL SYSTEM (ILA ACTIVVE): A RETROSPECTIVE DATA ANALYSIS
ALEXANDER HERMANN, THOMAS STAUDINGER, ANDJA BOJIC, KATHARINA RISS, PHILIPP WOHLFARTH, OLIVER ROBAK, WOLFGANG R. SPERR, PETER SCHELLONGOWSKI
DEPARTMENT OF MEDICINE I, INTENSIVE CARE UNIT 1312, MEDICAL UNIVERSITY VIENNA

Method

- Retrospective Data Analysis, Period: March 2012 – July 2013
- 12 patients undergoing ECCO2-R (extracorporeal CO2 removal) with the iLA activve® (Definition ECCO2-R in this institution: blood flow up to max. 2l, 22 or 24 Fr. double lumen cannula)
- 6 patients with primarily hypercapnic lung failure
  - Indications: bridging to lung transplantation / re-transplantation, AECOPD, refractory status asthmaticus, infectious triggered exacerbation of drug-induced lung fibrosis
  - Goal of ECCO2-R for this group of patients:
    - Enabling spontaneous breathing or weaning from mechanical ventilation
    - Avoidance of intubation for AECOPD patients
- 6 Patients with primarily hypoxic lung failure
  - This group of patients did not fulfill criteria for full ECMO support
  - They underwent highly invasive mechanical ventilation, 4 of these patients had been ventilated for more than 2 weeks before ECCO2-R
  - Goal of ECCO2-R for this group of patients:
    - To achieve less invasive ventilation settings by reducing tidal volumes, thus enabling higher PEEP levels or spontaneous breating
- 4 Patients were cannulated with 24 Fr., 8 Patients with 22 Fr. NovaPort® twin double lumen cannulas
  - 22 Fr. = jugular vascular access (1. choice)
  - 24 Fr. = femoral vascular access (sedated patients with other catheters inserted into the right jugular vein, very small jugular vein, or presence of thrombosis by ultrasound)
- iLA activve® iLA® Kits were used for all patients
- Target blood flow rate 1l up to max. 2l, target aPTT 50-60 seconds, venous suction pressure was kept below 80mmHg
Clinical Results:

- Within the first 4 hours on the iLA activve®, effective CO\textsubscript{2} removal was observed in all patients with concomitant normalization of pH.
- Tidal volumes, PIP as well as minute volumes could be reduced significantly within the first 24 hours.
- Change in patients ventilation situation:
  - Five Patients were awake and breathing spontaneously during ECCO\textsubscript{2}-R
  - Avoidance of intubation in one patient, treated for failure of noninvasive ventilation
  - Extubation of one patient the day following initiation of ECCO\textsubscript{2}-R
  - Weaning to assisted spontaneous breathing via tracheostomy cannula allowing communication and mobilization after 2 (2 Pat.) and 3 (1 Pat.) days.
- Results:
  - Six patients were successfully weaned from the system and survived to hospital discharge.
  - One patient had to be switched to VV-ECMO due to deterioration of oxygenation on the second day and survived (definition VV-ECMO in this institution is amongst others: blood flow > 2 l, and cannulation using 27 Fr. or 31 Fr. double lumen cannulas, if necessary two single lumen cannulas).
  - Five patients died while being treated. Nonsurvivors had a significantly poorer oxygenation and were ventilated significantly longer before initiation of ECCO\textsubscript{2}-R.
  - Primarily hypercapnic respiratory failure was associated with a better outcome.
- Complications:
  - In one patient, a retroperitoneal hematoma occurred immediately after cannulation of the femoral vein, probably because of inadvertent puncture of the artery.
  - In one patient the system had to be changed four times due to clotting of the membrane after 7,8,14 and 20 days.
  - In another patient, a system change due to clotting was necessary after 3 days.

Conclusion

- Benefits of the iLA activve® low flow therapy:
  - Easy insertion of the cannula.
  - Simple filling and starting the extracorporeal service with the iLA activve®.
  - A low resistance gas exchange membrane especially optimized for low flow- and mid-range blood flows.
  - Patient mobilization.
  - The main results of our retrospective analysis show that the iLA activve® removed CO\textsubscript{2} efficiently and enabled fast resolution of acidosis. As a consequence, a significant reduction in inspiratory pressures and minute ventilation could be achieved protective ventilation to avoid ventilator-associated lung injury to improve outcome.